TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05965739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BrainHQ/Active Comparator Activity
Description: BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BrainHQ
Description: BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PASC CoRE
Description: PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-active
Description: Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS-sham
Description: tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
Study: NCT05268419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: Inhalation of 35%-ethanol spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water Distilled
Description: Inhalation of water distilled spray
Study: NCT05312476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
Description: 1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group).
Study: NCT05017649

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sampling.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sampling.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sampling.
Study: NCT06555497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical 1% methotrexate gel
Description: topical 1% methotrexate gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate 0.05% ointment
Description: clobetasol propionate 0.05% ointment
Study: NCT05491109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venous Assistance and Contracture Management System (VACOM)
Description: Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Assistance and Contracture Management System (VACOM)
Description: Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
Study: NCT05931640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plyometric Training
Description: Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
Study: NCT04874116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging
Description: Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile text messaging
Description: Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
Study: NCT05952856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT05856227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril
Description: Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
Study: NCT05087628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-3279
Description: Bi-specific antibody-based molecule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04991324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 24,000 IU cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 24,000 IU cholecalciferol
Study: NCT05842122

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Client-sustained delivery of pharmacy PrEP/PEP
Description: * Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 250 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 0 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementor-sustained delivery of pharmacy PrEP/PEP
Description: * Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 250 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselor-supported delivery of pharmacy PrEP/PEP
Description: * Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery with support from a HTS counselor (to assist with screening and HIV testing)~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to clinic-based PrEP/PEP
Description: * Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) referral to clinic-based PrEP/PEP services~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP referral~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP referral \*Pharmacies paid by the research team (i.e., the implementer in this trial)
Study: NCT06425133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up
Study: NCT05229055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: giving ketamine intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: giving ketamine intranasal
Study: NCT05762887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Group
Description: The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The probiotic group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The placebo group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
Study: NCT05305131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and gemcitabine
Description: Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.
Description: Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
Study: NCT04680052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered IV for 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab will be administered IV on cycles 1 - 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: Rituximab will be administered IV on cycles 1 - 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered PO for 12 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lenalidomide
Description: Lenalidomide will be administered PO for 12 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered IV for 12 cycles
Study: NCT06425133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Fresh tumor biopsy at baseline and week 8
Study: NCT04948489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norethindrone acetate (NETA)
Description: 5mg of the NETA capsule by mouth daily for 12 months
Study: NCT06425133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Fresh tumor biopsy at baseline and week 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.
Study: NCT04948489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule everyday for 12 months
Study: NCT06124404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
Study: NCT06129955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pucotenlimab Combined With Lenvatinib
Description: Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
Study: NCT06425133

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regorafenib + metronomic chemotherapy
Description: • Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.~* Metronomic chemotherapy will be administrated as following:Cyclophosphamide: 50 mg per os, daily, for 6 months,Capecitabine: 625mg/m²/orally twice daily, for 6 months.~* Low-dose Aspirin: 75 mg orally, daily, until progression.
Study: NCT05249543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified protocol
Description: Transdiagnostic cognitive-behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis-specific cognitive-behavioral therapy
Description: Diagnosis-specific cognitive-behavioral therapy
Study: NCT05176067

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Three-dimensional Radiotherapy
Description: Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
Study: NCT05035173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Clinic Assessments
Description: Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Clinic Assessments
Description: Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Clinic Nurse Resource
Description: Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Clinic Dietitian Resource
Description: Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise.
Study: NCT06090799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-3032
Description: Single dose at varying dosage levels depending on treatment assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-3032 Placebo
Description: Single dose at varying dosage levels depending on treatment assignment
Study: NCT05573308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Aligners with Dental Monitoring
Description: Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Aligners
Description: Removabale orthodontics appliances

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Aligners
Description: Removabale orthodontics appliances
Study: NCT06548022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rare Group Problem Management Plus
Description: The World Health Organization's Group Problem Management Plus (Group PM+) intervention has been demonstrated to effectively provide psychological help for adults impaired by distress in communities exposed to adversity. Investigators will test an adapted model for use on-line and with family caregivers of children with rare diseases. Managing Stress. Teaching participants a brief stress management strategy will help them better manage problems related to anxiety and stress. Managing Problems. This is a strategy to apply in situations where a participant is experiencing practical problems (e.g. conflict in the family). Get Going, Keep Doing. This strategy targets depression and inactivity. Strengthening Social Support. Individuals with emotional problems can be isolated from supportive people and organizations. Strengthening social support promotes well-being. Staying Well and Looking Forward. This is a review, ends with a closing ceremony.
Study: NCT06036368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
Description: This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
Study: NCT06241846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201 for Injection
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201 for Injection
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
Study: NCT05214573

Intervention type: DRUG
Intervention: Glucagon like peptide 1 receptor agonist
Description: Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication

Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 inhibitor
Description: Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor

Intervention type: DRUG
Intervention: Dipeptidyl Peptidase 4 Inhibitor
Description: Patients in the data who filled a dipeptidyl peptidase-4 inhibitor

Intervention type: DRUG
Intervention: Sulfonylurea
Description: Patients in the data who filled a sulfonylurea
Study: NCT05660538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.